Latest Ratios: P/E Ratio -2.1x · EV/EBITDA N/A · ROE -198.1%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $367M | $182M | $105M | $770M | $609M | $1.8B | $4.1B | $1.5B | $1.1B | $1.2B | $523M |
| Enterprise Value | $297M | $112M | $8M | $694M | $511M | $1.6B | $4.0B | $1.3B | $969M | $1.1B | $373M |
| P/E Ratio → | -2.08 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 9.06 | 4.49 | 3.24 | 9.85 | 30.90 | 70.28 | 45.29 | 72.09 | 33.55 | 90.26 | 86.39 |
| P/B Ratio | 12.20 | 6.67 | 0.78 | 2.20 | 1.69 | 3.24 | 10.44 | 5.64 | 4.54 | 5.96 | 3.88 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.76 | 0.25 | 8.89 | 25.95 | 63.35 | 44.04 | 61.90 | 30.34 | 82.02 | 61.57 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 92.2% | 67.9% | 80.2% | -74.1% | -372.0% | -183.9% | -505.8% | -841.3% |
| Operating Margin | -245.2% | -245.2% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | -873.6% | -1605.6% |
| Net Profit Margin | -395.0% | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | -876.5% | -1605.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -198.1% | -198.1% | -98.1% | -43.2% | -48.2% | -40.6% | -35.4% | -53.6% | -49.5% | -70.2% | -377.5% |
| ROA | -60.6% | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -39.9% | -51.3% |
| ROIC | — | — | -120.8% | -47.2% | -53.0% | -44.1% | -60.7% | -113.0% | -74.6% | -227.0% | — |
| ROCE | -49.1% | -49.1% | -71.7% | -38.0% | -41.7% | -33.7% | -28.0% | -33.8% | -31.5% | -45.0% | -57.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.81 | 2.81 | 0.26 | 0.14 | 0.12 | 0.05 | 0.07 | 0.11 | 0.14 | 0.16 | 0.26 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.56 | -0.72 | -0.22 | -0.27 | -0.32 | -0.29 | -0.80 | -0.43 | -0.54 | -1.12 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -24.94 | -24.94 | — | — | — | — | — | — | — | -122.03 | — |
Net cash position: cash ($147M) exceeds total debt ($77M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.54 | 3.54 | 3.75 | 5.39 | 5.94 | 10.82 | 7.20 | 7.74 | 10.44 | 9.05 | 5.66 |
| Quick Ratio | 3.54 | 3.54 | 3.75 | 5.39 | 5.94 | 10.82 | 7.20 | 7.74 | 10.36 | 9.00 | 5.61 |
| Cash Ratio | 3.17 | 3.17 | 3.50 | 5.11 | 5.73 | 10.66 | 6.91 | 7.62 | 10.28 | 8.97 | 5.60 |
| Asset Turnover | — | 0.22 | 0.09 | 0.16 | 0.04 | 0.04 | 0.16 | 0.04 | 0.08 | 0.04 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 31.07 | 44.61 | 34.28 |
| Days Sales Outstanding | — | 136.70 | 183.73 | 47.59 | 95.27 | 3.82 | 24.33 | 7.43 | 0.34 | 18.05 | 5.31 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $89M | $82M | $76M | $69M | $68M | $59M | $50M | $47M | $40M | $32M |
Clinical binary outcome dependency
As reported in recent financial filings, Editas trades at a price-to-sales ratio of 6.89, a valuation that appears to be driven by speculative interest in its Cas12a intellectual property rather than any fundamental alignment with current, highly intermittent and non-recurring milestone-based revenue streams.
The current P/S multiple suggests that investors are pricing the company as a long-duration option on future clinical success rather than a traditional operating business. Given the absence of positive earnings or cash flow, standard valuation metrics like P/E are non-informative, and the premium relative to book value warrants caution regarding potential future dilution.
Based on the company's reported figures, the net margin of -395.01% underscores a profound lack of operational profitability, as the firm's heavy investment in R&D continues to outpace its ability to generate sustainable revenue from its current collaboration-heavy business model.
The 100% gross margin is a temporary artifact of the company's pre-commercial status and should not be interpreted as a sign of pricing power or operational efficiency. Investors should monitor the operating margin closely, as it reflects the high fixed costs of clinical trial execution that currently prevent the company from achieving a self-sustaining financial profile.
According to recent quarterly data, the company's asset turnover ratio remains extremely low at 0.02, indicating that the firm's capital base is not being effectively utilized to generate revenue, which is typical for a pre-revenue biotech firm focused on long-term research and development.
The erratic nature of the cash conversion cycle, driven by the timing of milestone payments, suggests that management lacks control over the predictability of its working capital. This inefficiency is a structural reality of the current business model and implies that the company remains highly vulnerable to liquidity shocks between major partnership inflows.
As evidenced by the sharp increase in the debt-to-equity ratio to 16.33 in 2026Q1, the company's reliance on debt has escalated significantly, reflecting a desperate need for capital as the equity base is eroded by persistent and substantial operating losses.
The rapid deterioration of the balance sheet suggests that the company is exhausting its financial flexibility, making it increasingly dependent on external financing to maintain its clinical programs. This trend warrants further investigation into the company's ability to secure non-dilutive funding before its current cash runway is fully depleted.
The price-to-book ratio of 9.27 is frequently misapplied to Editas, as it obscures the fact that the company's book value is rapidly declining due to accumulated deficits, rendering the metric an unreliable indicator of the firm's true intrinsic value or its underlying research potential.
Investors should instead focus on the 'Cash Runway' and 'Net Cash Used in Operating Activities' as more accurate gauges of the company's health. Relying on book value in a pre-revenue biotech context ignores the reality that the firm's most valuable assets are intangible and often not fully captured on the balance sheet.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EDIT stock.
Editas Medicine, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
Editas Medicine, Inc.'s return on equity (ROE) is -198.1%. The historical average is -101.4%.
Based on historical data, Editas Medicine, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Editas Medicine, Inc. has 100.0% gross margin and -245.2% operating margin.